Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07251-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Xiaoyi Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Capital's Funds for Health Improvement and Research, the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: To assess the diagnostic performance and the whole-body heterogeneity of HER2 expression on Al18F-NOTA-HER2-BCH PET/CT in patients with HER2-low breast cancer. METHODS: In this prospective study conducted from November 2021 to March 2024, participants with HER2-low breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-low (immunohistochemistry score of 1 + or 2 + without HER2 gene amplification on in situ hybridization). PET/CT images were acquired 3.5 h after injection of 200 MBq of Al18F-NOTA-HER2-BCH. The maximum standardized uptake value (SUVmax) and target-to-background ratios (TBR) were used to quantify tracer uptake. RESULTS: Fifty-two participants with HER2-low breast cancer (mean age, 53.0 ± 11.0; 52 females) underwent Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT with paired tumor biopsies. No adverse events occurred. The median SUVmax and TBR of 52 HER2-low biopsy lesions on Al18F-NOTA-HER2-BCH PET/CT were lower than that on 18F-FDG PET/CT (6.6 vs. 10.5, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
- Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
- Breast Disease Center, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China. wangzhenguang@qdu.edu.cn.
- Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. songguohong918@hotmail.com.
ORCID-Profile: Zhi Yang
Förderung
- National Natural Science Foundation of China
- the Capital's Funds for Health Improvement and Research
- the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute
- and Science Foundation of Peking University Cancer Hospital
- Isotope and Pharmaceutical Innovation Fund of National Engineering Research Center of Isotope & Pharmaceutical
- Nuclear energy development research project
- the Capital’s Funds for Health Improvement and Research
Zitieren
APA
Guo, X., Liang, X., Li, B., Mao, Y., Zhou, N., Liu, J., Yang, G., Wang, Z., Song, G., & Yang, Z. (2025). Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07251-w
Vancouver
Guo X, Liang X, Li B, Mao Y, Zhou N, Liu J, et al. Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07251-w
BibTeX
@article{Guo2025,
author = {Guo, Xiaoyi and Liang, Xu and Li, Ben and Mao, Yan and Zhou, Nina and Liu, Jiayue and Yang, Guangjie and Wang, Zhenguang and Song, Guohong and Yang, Zhi},
title = {Al18F-NOTA-HER2-BCH versus 18F-FDG PET/CT in evaluating newly diagnosed HER2-low breast cancer patients},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07251-w}
}
EUVIMED